CClinicalTrials.gg
Status unknownNCT04804176Updated Mar 24, 2021

Study on the Mode and Mechanism of Ultra-low Frequency rTMS for Sleep Disorders in Patients With Parkinson's Disease

An interventional study of Ultra-low frequency repetitive transcranial magnetic stimulation in Repetitive Transcranial Magnetic Stimulation, Parkinson Disease and Sleep Disorder, sponsored by Qianfoshan Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-03-24.

Sponsored by Qianfoshan Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Enrolling by invitation — may be out of date.

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Dec 2019, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.

Read the detailed description

Parkinson's disease is the second most common chronic neurodegenerative disease.At present, researchers focus not only on the motor symptoms of Parkinson's disease, but also on the non-motor symptoms of Parkinson's disease (including mood disorders, sleep disorders, cognitive decline, and autonomic nervous kinetic disorder, etc.).The principle of transcranial magnetic stimulation is based on the electromagnetic principle proposed by Faraday. When an electrifying coil is suspended over the scalp at a certain distance, the magnetic field generated by the coil current and the electric field generated by the magnetic field can reach the skull and directly or indirectly affect the synapses and neurons in the brain.The study by giving a sleep disorder Parkinson's disease patients with different patterns of ultra-low frequency transcranial magnetic stimulation or sham stimulation, scale for assessment of the patients were observed, hematology and imaging changes before and after therapy, clear ultra-low frequency transcranial magnetic stimulation for sleep disorder Parkinson's disease treatment, to explore the mechanism of action, compare the difference between different modes.

02

Conditions studied

  • Repetitive Transcranial Magnetic Stimulation
  • Parkinson Disease
  • Sleep Disorder

Keywords

  • repetitive transcranial magnetic stimulation
  • Parkinson's disease
  • sleep disorder
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,081 are open to participants now.

This study's planned enrollment of 99 is above the median of 40 across 3,293 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Qianfoshan Hospital is the lead sponsor of 140 studies on the registry; 73 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • in line with international Movement disorders association (the Movement Disorder Society, MDS) in 2015 the diagnosis of Parkinson's disease diagnosis standard and China standard (2016)
  • can cooperate to complete rating scale, the sleep monitoring, imaging and blood test
  • have a sleep disorder
  • aged 18 to 70 years old
  • agree to participate in this experiment, and have signed the informed consent

Exclusion criteria

Exclusion Criteria:

  • superposition of diagnosed with Parkinson's syndrome
  • secondary diagnosed Parkinson's syndrome
  • is equipped with heart pacemakers and other metal implants
  • cannot achieve scale assessment
  • has significant malignant diseases
  • has a history of seizures
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
99 participants (estimated)

Study arms

  • Active comparator
    5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation

    The study used 5-HT mode of Ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS.

    Device: Ultra-low frequency repetitive transcranial magnetic stimulation

  • Active comparator
    GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation

    The study used GABA mode of ultra-low frequency repetitive transcranial magnetic stimulation for 35 minutes once a day.Every 7 days is a cycle.The stimulus intensity was 400GS

    Device: Ultra-low frequency repetitive transcranial magnetic stimulation

  • Sham comparator
    the control group

    The instrument is not working, only in exhaust mode.

    Device: Ultra-low frequency repetitive transcranial magnetic stimulation

Interventions

  • DeviceUltra-low frequency repetitive transcranial magnetic stimulation

    Two different modes of the instrument were used to treat patients in groups, to compare the efficacy.

06

What researchers measure

Primary outcomes

  1. change from length of sleep at one week

    Sleep duration was monitored by polysomnography.It's measured in minutes.

    Time frame: one week

  2. change from ratio of stage 3 sleep in total sleep at one week

    The proportion of phase 3 sleep in total sleep was monitored by polysomnography.It's in percentages.

    Time frame: one week

  3. change from limb movement of sleep at one week

    The number of body movements during sleep was recorded by polysomnography.It's in units of times per night.

    Time frame: one week

  4. change from nocturnal arousal frequency at one week

    The number of nocturnal awakenings was recorded by polysomnography.It's in units of times per night.

    Time frame: one week

  5. change from Pittsburgh sleep quality index scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 2L, and the higher the score, the worse the sleep quality.

    Time frame: 1 day before treatment、1 day after treatment、1 week after treatment、1 moth after treatment

  6. Interleukin 6

    It plays an important role in central nervous system diseases. In PD, the increase of IL-6 is the body's self-defense mechanism to protect neurons, and the change of IL-6 in peripheral blood can reflect the change of injury aggravation and recovery.It is also associated with psychiatric symptoms, and IL-6 is elevated in major depression.

    Time frame: 1 day before treatment and 1 day after treatment

  7. change from the Epworth sleepiness scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The scale has an overall score range of 0 to 24, with higher scores indicating more severe sleepiness.

    Time frame: one week

  8. change from Parkinson's disease sleep scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 150. The higher the score, the better the sleep.

    Time frame: one week

  9. change from movement disorders association - comprehensive rating scale of Parkinson's disease at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 260, and the higher the score, the more severe the symptoms were.

    Time frame: one week

  10. change from Parkinson's disease quality of life scale one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 156, and the higher the score, the worse the quality of life.

    Time frame: one week

  11. change from Hamilton depression scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranged from 0 to 96, and the higher the score, the more severe the depression was.

    Time frame: one week

  12. change from Hamilton anxiety scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 56, and the higher the score, the more serious the anxiety.

    Time frame: one week

  13. change from simple mental state scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.

    Time frame: one week

  14. change from Montreal cognitive assessment scale at one week

    The scale was evaluated on the day before treatment and the day after treatment, which was based on scores.The total score of the scale ranges from 0 to 30, and the lower the score, the more severe the cognitive impairment.

    Time frame: one week

  15. change from magnetic resonance imaging of the brain at one month

    The ADC values of sleep-related brain tissues were measured by diffusion weighted magnetic resonance imaging of the brain.Compare the difference between the measured results on both sides of the same site and record the difference.

    Time frame: one month

07

Study locations

1 site
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04804176
Lead sponsor
Qianfoshan Hospital
Responsible party
Lili Cao (Professor, Qianfoshan Hospital) — Principal investigator
First posted
Mar 18, 2021
Start date
Dec 20, 2019
Primary completion
Dec 20, 2021 (estimated)
Completion
Apr 20, 2022 (estimated)
Last update
Mar 24, 2021

Study contacts

Xiuhua Li, MD
principal investigator · Qianfoshan Hospital,The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion